Minimum Bio

MINIMUM bio is a biotech company that aims to revolutionize drug discovery by accelerating early phase R&D in the pharmaceutical sector, saving years and hundreds of millions of dollars in drug development costs. MINIMUM bio has developed a versatile, high throughput discovery technology with broad applications in the development of new therapeutic products and the repositioning of existing drugs. The Company’s expertise and know-how is based on our phage display technology platform that permits us to rapidly identify proteins that bind to bioactive molecules of interest. The Company has repurposed antibody phage display for drug target discovery and believes that this platform is a powerful method that can also be used to identify protein targets of small molecules, biologics and other bioactive compounds, and has significant advantages over conventional and mass spectrometry-based approaches. Advantages include: increased speed, less background and less bias toward common, high-abundance, but low affinity targets. Over the past 15 years we have been improving and refining the Phage Display technique (‘Mercurious®’) to the point where we can now rapidly isolate the protein binding partner(s) for any small molecule, biologic or natural product. Our flagship Mercurious platform is designed to create a new model for early-stage drug discovery. The platform harnesses an antibody drug discovery platform and repurposes it for drug target discovery, combining advances in molecular biology, next generation sequencing and machine learning into a single integrated architecture for rapid and agnostic drug target discovery with the goal of accelerating the rate of drug development. The Mercurious platform builds on our core target identification technology and presents a seamless pipeline that will address target identification challenges for the global pharmaceutical industry in a customizable, scalable, and cost-competitive manner.